Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8191 to 8205 of 8899 results

  1. Newer drugs for epilepsy in adults (TA76)

    This guideline has been updated and replaced by NICE guideline CG137.

    Withdrawn guidance

  2. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1042

    Withdrawn guidance

  3. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)

    This guidance has been updated and replaced by NICE technology appraisal guidance 984.

    Withdrawn guidance

  4. The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

    This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]

    Withdrawn guidance

  5. Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) (TA700)

    This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.  

    Withdrawn guidance

  6. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1043.

    Withdrawn guidance

  7. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) (TA762)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1040.

    Withdrawn guidance

  8. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

    Withdrawn guidance

  9. The clinical effectiveness and cost effectiveness of anakinra for rheumatoid arthritis (TA72)

    This appraisal has been updated and replaced by NICE guideline CG79. 

    Withdrawn guidance

  10. Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1110.

    Withdrawn guidance

  11. Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA804.

    Withdrawn guidance

  12. Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

    This guidance has been updated and replaced by NICE technology appraisal guidance 946.

    Withdrawn guidance

  13. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (CG101)

    This guideline has been updated and replaced by NICE guideline NG115.

    Withdrawn guideline

  14. Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)

    This guideline has been updated and replaced by NICE guideline NG240.

    Withdrawn guideline

  15. Motor neurone disease: non-invasive ventilation (CG105)

    This guideline has been updated and replaced by NICE guideline 42. 

    Withdrawn guideline